BNP: Pathophysiological and potential therapeutic roles in acute congestive heart failure

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Controversy persists regarding the acute responsiveness of atrial (ANP) and brain (BNP) natriuretic peptides in pathophysiological conditions such as acute heart failure (AHF). This study was designed to test the hypothesis that AHF is characterized by selective activation of ANP, but not BNP. We also hypothesized that BNP replacement in AHF would reduce cardiac filling pressures, increase sodium excretion, and inhibit circulating renin. Two groups of anesthetized dogs underwent rapid left ventricular pacing to induce AHF. Group 1 (n = 7) served as control and group 2 (n = 7) received canine BNP (10 ng · kg-1 · min-1). Cardiorenal parameters, circulating natriuretic peptides, 3',5'-cyclic guanosine monophosphate (cGMP), and plasma renin activity (PRA) were determined at baseline and during AHF in both groups. AHF was characterized by reductions in cardiac output (2.3 ± 0.2 vs. 3.7 ± 0.3 l/min, P < 0.05), pulmonary capillary wedge pressure (PCWP; 11.7 ± 0.8 vs. 5.1 ± 0.3 mmHg, P < 0.05), and selective activation of ANP (250 ± 51 vs. 39 ± 13 pg/ml, P < 0.05), with no increase in circulating BNP (49 ± 15 vs. 50 ± 16 pg/ml, P = not significant). Compared with control, exogenous supplemental BNP in AHF resulted in marked increases in circulating cGMP (65 ± 6 vs. 18 ± 5 pg/ml, P < 0.05), with reductions in PCWP (9.1 ± 0.9 vs. 12.9 ± 1.1 mmHg, P < 0.05) and increased urinary sodium excretion (120 ± 36.8 vs. 24 ± 6.3 μeq/min, P < 0.05) via reductions in distal tubular sodium reabsorption (94.3 ± 1.8 vs. 98.0 ± 0.4%, P < 0.05). Exogenous BNP prevented the increase in PRA that occurred in the control group. We conclude that AHF is characterized by a failure to increase circulating BNP underscoring differential physiological and pathophysiological roles for ANP and BNP in states of immediate cardiac overload. These studies also support a potential role for BNP in the therapeutics of AHF.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Volume272
Issue number4 41-4
StatePublished - 1997

Fingerprint

Heart Failure
Atrial Natriuretic Factor
Renin
Therapeutics
Sodium
Cyclic GMP
Control Groups
Natriuretic Peptides
Pulmonary Wedge Pressure
Brain Natriuretic Peptide
Cardiac Output
Canidae
Dogs
Pressure

Keywords

  • natriuretic peptide system
  • sodium excretion

ASJC Scopus subject areas

  • Physiology

Cite this

@article{2aadd5fade2b46d4977c197e39318fb7,
title = "BNP: Pathophysiological and potential therapeutic roles in acute congestive heart failure",
abstract = "Controversy persists regarding the acute responsiveness of atrial (ANP) and brain (BNP) natriuretic peptides in pathophysiological conditions such as acute heart failure (AHF). This study was designed to test the hypothesis that AHF is characterized by selective activation of ANP, but not BNP. We also hypothesized that BNP replacement in AHF would reduce cardiac filling pressures, increase sodium excretion, and inhibit circulating renin. Two groups of anesthetized dogs underwent rapid left ventricular pacing to induce AHF. Group 1 (n = 7) served as control and group 2 (n = 7) received canine BNP (10 ng · kg-1 · min-1). Cardiorenal parameters, circulating natriuretic peptides, 3',5'-cyclic guanosine monophosphate (cGMP), and plasma renin activity (PRA) were determined at baseline and during AHF in both groups. AHF was characterized by reductions in cardiac output (2.3 ± 0.2 vs. 3.7 ± 0.3 l/min, P < 0.05), pulmonary capillary wedge pressure (PCWP; 11.7 ± 0.8 vs. 5.1 ± 0.3 mmHg, P < 0.05), and selective activation of ANP (250 ± 51 vs. 39 ± 13 pg/ml, P < 0.05), with no increase in circulating BNP (49 ± 15 vs. 50 ± 16 pg/ml, P = not significant). Compared with control, exogenous supplemental BNP in AHF resulted in marked increases in circulating cGMP (65 ± 6 vs. 18 ± 5 pg/ml, P < 0.05), with reductions in PCWP (9.1 ± 0.9 vs. 12.9 ± 1.1 mmHg, P < 0.05) and increased urinary sodium excretion (120 ± 36.8 vs. 24 ± 6.3 μeq/min, P < 0.05) via reductions in distal tubular sodium reabsorption (94.3 ± 1.8 vs. 98.0 ± 0.4{\%}, P < 0.05). Exogenous BNP prevented the increase in PRA that occurred in the control group. We conclude that AHF is characterized by a failure to increase circulating BNP underscoring differential physiological and pathophysiological roles for ANP and BNP in states of immediate cardiac overload. These studies also support a potential role for BNP in the therapeutics of AHF.",
keywords = "natriuretic peptide system, sodium excretion",
author = "Grantham, {J. Aaron} and Borgeson, {Daniel Dean} and Burnett, {John C Jr.}",
year = "1997",
language = "English (US)",
volume = "272",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "4 41-4",

}

TY - JOUR

T1 - BNP

T2 - Pathophysiological and potential therapeutic roles in acute congestive heart failure

AU - Grantham, J. Aaron

AU - Borgeson, Daniel Dean

AU - Burnett, John C Jr.

PY - 1997

Y1 - 1997

N2 - Controversy persists regarding the acute responsiveness of atrial (ANP) and brain (BNP) natriuretic peptides in pathophysiological conditions such as acute heart failure (AHF). This study was designed to test the hypothesis that AHF is characterized by selective activation of ANP, but not BNP. We also hypothesized that BNP replacement in AHF would reduce cardiac filling pressures, increase sodium excretion, and inhibit circulating renin. Two groups of anesthetized dogs underwent rapid left ventricular pacing to induce AHF. Group 1 (n = 7) served as control and group 2 (n = 7) received canine BNP (10 ng · kg-1 · min-1). Cardiorenal parameters, circulating natriuretic peptides, 3',5'-cyclic guanosine monophosphate (cGMP), and plasma renin activity (PRA) were determined at baseline and during AHF in both groups. AHF was characterized by reductions in cardiac output (2.3 ± 0.2 vs. 3.7 ± 0.3 l/min, P < 0.05), pulmonary capillary wedge pressure (PCWP; 11.7 ± 0.8 vs. 5.1 ± 0.3 mmHg, P < 0.05), and selective activation of ANP (250 ± 51 vs. 39 ± 13 pg/ml, P < 0.05), with no increase in circulating BNP (49 ± 15 vs. 50 ± 16 pg/ml, P = not significant). Compared with control, exogenous supplemental BNP in AHF resulted in marked increases in circulating cGMP (65 ± 6 vs. 18 ± 5 pg/ml, P < 0.05), with reductions in PCWP (9.1 ± 0.9 vs. 12.9 ± 1.1 mmHg, P < 0.05) and increased urinary sodium excretion (120 ± 36.8 vs. 24 ± 6.3 μeq/min, P < 0.05) via reductions in distal tubular sodium reabsorption (94.3 ± 1.8 vs. 98.0 ± 0.4%, P < 0.05). Exogenous BNP prevented the increase in PRA that occurred in the control group. We conclude that AHF is characterized by a failure to increase circulating BNP underscoring differential physiological and pathophysiological roles for ANP and BNP in states of immediate cardiac overload. These studies also support a potential role for BNP in the therapeutics of AHF.

AB - Controversy persists regarding the acute responsiveness of atrial (ANP) and brain (BNP) natriuretic peptides in pathophysiological conditions such as acute heart failure (AHF). This study was designed to test the hypothesis that AHF is characterized by selective activation of ANP, but not BNP. We also hypothesized that BNP replacement in AHF would reduce cardiac filling pressures, increase sodium excretion, and inhibit circulating renin. Two groups of anesthetized dogs underwent rapid left ventricular pacing to induce AHF. Group 1 (n = 7) served as control and group 2 (n = 7) received canine BNP (10 ng · kg-1 · min-1). Cardiorenal parameters, circulating natriuretic peptides, 3',5'-cyclic guanosine monophosphate (cGMP), and plasma renin activity (PRA) were determined at baseline and during AHF in both groups. AHF was characterized by reductions in cardiac output (2.3 ± 0.2 vs. 3.7 ± 0.3 l/min, P < 0.05), pulmonary capillary wedge pressure (PCWP; 11.7 ± 0.8 vs. 5.1 ± 0.3 mmHg, P < 0.05), and selective activation of ANP (250 ± 51 vs. 39 ± 13 pg/ml, P < 0.05), with no increase in circulating BNP (49 ± 15 vs. 50 ± 16 pg/ml, P = not significant). Compared with control, exogenous supplemental BNP in AHF resulted in marked increases in circulating cGMP (65 ± 6 vs. 18 ± 5 pg/ml, P < 0.05), with reductions in PCWP (9.1 ± 0.9 vs. 12.9 ± 1.1 mmHg, P < 0.05) and increased urinary sodium excretion (120 ± 36.8 vs. 24 ± 6.3 μeq/min, P < 0.05) via reductions in distal tubular sodium reabsorption (94.3 ± 1.8 vs. 98.0 ± 0.4%, P < 0.05). Exogenous BNP prevented the increase in PRA that occurred in the control group. We conclude that AHF is characterized by a failure to increase circulating BNP underscoring differential physiological and pathophysiological roles for ANP and BNP in states of immediate cardiac overload. These studies also support a potential role for BNP in the therapeutics of AHF.

KW - natriuretic peptide system

KW - sodium excretion

UR - http://www.scopus.com/inward/record.url?scp=0030921427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030921427&partnerID=8YFLogxK

M3 - Article

C2 - 9140004

VL - 272

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 4 41-4

ER -